Biora Therapeutics, Inc.

OTCPK:BIOR.Q Stock Report

Market Cap: US$597.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biora Therapeutics Past Earnings Performance

Past criteria checks 0/6

Biora Therapeutics has been growing earnings at an average annual rate of 21.3%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been declining at an average rate of 87.6% per year.

Key information

21.28%

Earnings growth rate

85.61%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-87.64%
Return on equityn/a
Net Margin-3,988.12%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Seeking Alpha • Sep 13

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics (NASDAQ:BIOR) said on Tuesday the United States Patent and Trademark Office had issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The patent is for methods for using an ingestible device to treat a disease or condition in a patient using jet delivery of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist formulation to the small intestine. GLP-1 receptor agonists are a class of drug approved for type 2 diabetes and weight loss.
Seeking Alpha • Aug 17

Biora Therapeutics: Checking In On The Transformation

Today, we take our first look at the rebranded/refocused Biora Therapeutics in 2022. When we last looked at this company, it was still transitioning from being a genetic testing company to being a developmental drug company. How is the transformation working out to date?  An investment analysis follows in the paragraphs below. Everyone thinks of changing the world, but no one thinks of changing himself." - Leo Tolstoy Today, we put Biora Therapeutics (BIOR) in the spotlight for the first time this year. When we last looked at this entity in the fourth quarter of last year, it was still transitioning from being an entity called Progenity (PROG). The company was in the middle of transforming from its focus as a genetic testing company to being a company focused on developing its drug candidates. Second quarter results just hit the wires this week. Therefore, it seems an opportune time to peak back in on this small cap concern and check in on how its transformation is proceeding. An analysis follows below. Seeking Alpha Company Overview: August Company Presentation The refocused Biora Therapeutics is still based in San Diego. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the GI tract to enhance the treatment of inflammatory bowel diseases. Leadership believe this approach has plenty of potential targets, including holding great promise to more effectively treat Ulcerative Colitis, a large indication. It also is targeting IBD. According to management on its last earnings conference call. Annual global sales for UC drugs are estimated to be approximately $7 billion and the inflammatory bowel disease or IBD space overall is about $19 billion globally. " August Company Presentation August Company Presentation Here is the current development plan for the most advanced candidate in this developmental area, PGN - 600, which is combination of Biora's device and their proprietary formulation of tofacitinib. August Company Presentation The company is also focused on an oral delivery approach via ingestible capsules as an alternative to intramuscular injectable vaccines. This method could eventually see use for proteins as well as monoclonal antibodies. August Company Presentation The replacement of needle injection via an easy to take oral capsule could yield more effective results in a variety of disease areas. The company has a research collaboration with Ionis Pharmaceuticals (IONS) in these initial efforts. Preclinical activities should run into the third quarter of 2023, and are scheduled to start early stage clinical activities by the end of that year. The company estimates the area of the diabetes market it is targeting to be well over $20 billion by 2025. August Company Presentation Management believes the management of diabetes could be vastly improved to name one large target area. August Company Presentation With two core developmental focus areas, the company has numerous candidates in the pipeline. The company's portfolio has numerous patents around the company's intellectual property. That said, its candidates all in the very early stages of the long developmental lifecycle as can be seen above. August Company Presentation
Seeking Alpha • Aug 10

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics (NASDAQ:BIOR), a biotech focused on oral biotherapeutics, surged ~30% on Wednesday to record the highest intraday gain since November after the company announced promising topline data from a study for its targeted therapeutics platform. The recently completed PM-602 was designed to evaluate the Drug Delivery System Capsule (DDS) in patients with ulcerative colitis in a fasted state. According to the data, the device was well tolerated and performed as expected in all UC patients after a single oral ingestion. Accurately identifying the entry into the colon, the device released a saline solution payload that included radioisotopes, leading to distribution across the entire colon in all seven patients. Biora (BIOR) plans to release further information on the study after completing the analysis and intends to submit data for publication. “These human studies are key steps in advancing toward our PGN-600 clinical program, and they also demonstrate the potential of the platform for localized delivery of other drugs,” Chief Executive Adi Mohanty noted. Biora (BIOR) was previously identified as Progenity.

Revenue & Expenses Breakdown

How Biora Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:BIOR.Q Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-363526
30 Jun 241-873731
31 Mar 241-1113830
31 Dec 230-1243730
30 Sep 230-1223829
30 Jun 230-643325
31 Mar 230-523325
31 Dec 220-493824
30 Sep 221-1184227
30 Jun 221-1405233
31 Mar 221-1766741
31 Dec 211-1797346
30 Sep 211-1467649
30 Jun 211-1427549
31 Mar 21-16-1064848
31 Dec 200-1056048
30 Sep 2021-1427551
30 Jun 2039-2078955
31 Mar 20113-21812259
31 Dec 19144-22912063
30 Sep 19120-21111663
31 Dec 18128-12910149

Quality Earnings: BIOR.Q is currently unprofitable.

Growing Profit Margin: BIOR.Q is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BIOR.Q is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.

Accelerating Growth: Unable to compare BIOR.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOR.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).

Return on Equity

High ROE: BIOR.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 15:10
End of Day Share Price 2025/05/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biora Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Steven MahPiper Sandler Companies
Andrew CooperRaymond James & Associates